Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-07-26 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Ultomiris recommended in EU for children with PNH
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 3634G' and is dated '26 July 2021'. It details a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the expanded use of Ultomiris in the EU. The content is a press release announcing a regulatory/clinical development milestone, not a comprehensive financial report (like 10-K or IR) or a transcript. The presence of the RNS header and the nature of the announcement (regulatory recommendation) strongly suggest this is a general regulatory announcement distributed via the RNS system. Since it is a specific announcement that doesn't fit the other categories (like DIV, ER, or CT), the most appropriate classification is the general regulatory filing category, RNS.
2021-07-26 English
DIRECTORATE CHANGE
Foreign Filer Report
2021-07-22 English
Directorate Change
Board/Management Information Classification · 100% confidence The document is an official announcement released via RNS (Regulatory News Service) on July 22, 2021. The core content explicitly states the appointment of a new Non-Executive Director, Andreas Rummelt, following an acquisition. This directly relates to changes in the company's board of directors or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). Although it uses the RNS distribution system, the specific subject matter is too precise for the general 'RNS' fallback.
2021-07-22 English
FORM 6-K
Foreign Filer Report
2021-07-21 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2021-07-21 English
TOTAL VOTING RIGHTS
Foreign Filer Report
2021-07-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.